X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs NATCO PHARMA - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA NATCO PHARMA TORRENT PHARMA/
NATCO PHARMA
 
P/E (TTM) x 41.2 15.0 274.5% View Chart
P/BV x 5.8 3.8 152.4% View Chart
Dividend Yield % 0.9 1.2 75.5%  

Financials

 TORRENT PHARMA   NATCO PHARMA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
NATCO PHARMA
Mar-18
TORRENT PHARMA/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,5501,080 143.5%   
Low Rs1,144671 170.3%   
Sales per share (Unadj.) Rs354.7592.1 59.9%  
Earnings per share (Unadj.) Rs40.1188.4 21.3%  
Cash flow per share (Unadj.) Rs64.2206.3 31.1%  
Dividends per share (Unadj.) Rs14.008.25 169.7%  
Dividend yield (eoy) %1.00.9 110.3%  
Book value per share (Unadj.) Rs273.1833.6 32.8%  
Shares outstanding (eoy) m169.2236.90 458.6%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x3.81.5 256.7%   
Avg P/E ratio x33.64.6 723.1%  
P/CF ratio (eoy) x21.04.2 494.2%  
Price / Book Value ratio x4.91.1 469.4%  
Dividend payout %34.94.4 797.8%   
Avg Mkt Cap Rs m227,89732,311 705.3%   
No. of employees `00014.74.8 304.3%   
Total wages/salary Rs m11,3533,256 348.7%   
Avg. sales/employee Rs Th4,083.04,522.5 90.3%   
Avg. wages/employee Rs Th772.3674.0 114.6%   
Avg. net profit/employee Rs Th461.31,439.0 32.1%   
INCOME DATA
Net Sales Rs m60,02121,848 274.7%  
Other income Rs m2,988404 739.7%   
Total revenues Rs m63,00922,252 283.2%   
Gross profit Rs m13,4939,284 145.3%  
Depreciation Rs m4,086662 617.2%   
Interest Rs m3,085154 2,003.1%   
Profit before tax Rs m9,3108,872 104.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,5291,920 131.7%   
Profit after tax Rs m6,7816,952 97.5%  
Gross profit margin %22.542.5 52.9%  
Effective tax rate %27.221.6 125.5%   
Net profit margin %11.331.8 35.5%  
BALANCE SHEET DATA
Current assets Rs m52,62321,307 247.0%   
Current liabilities Rs m52,0225,920 878.7%   
Net working cap to sales %1.070.4 1.4%  
Current ratio x1.03.6 28.1%  
Inventory Days Days12073 163.3%  
Debtors Days Days76107 71.6%  
Net fixed assets Rs m85,01614,986 567.3%   
Share capital Rs m846369 229.3%   
"Free" reserves Rs m45,37630,353 149.5%   
Net worth Rs m46,22230,760 150.3%   
Long term debt Rs m41,1150-   
Total assets Rs m142,43237,151 383.4%  
Interest coverage x4.058.6 6.9%   
Debt to equity ratio x0.90-  
Sales to assets ratio x0.40.6 71.7%   
Return on assets %6.919.1 36.2%  
Return on equity %14.722.6 64.9%  
Return on capital %14.229.3 48.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m14,58010,322 141.3%   
Fx outflow Rs m3,6002,978 120.9%   
Net fx Rs m10,9807,343 149.5%   
CASH FLOW
From Operations Rs m8,9424,636 192.9%  
From Investments Rs m-47,070-11,155 422.0%  
From Financial Activity Rs m34,1746,509 525.0%  
Net Cashflow Rs m-3,655-18 20,305.6%  

Share Holding

Indian Promoters % 71.5 52.0 137.4%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 7.0 7.8 89.5%  
FIIs % 12.6 16.6 75.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 26.0 33.8%  
Shareholders   26,511 25,395 104.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   WOCKHARDT LTD.  J.B.CHEMICALS  ORCHID PHARMA LTD  DIVIS LABORATORIES  FULFORD INDIA  

Compare TORRENT PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Over 280 Points Lower; IT and Healthcare Stocks Witness Selling(Closing)

After trading on a negative note throughout the day, share markets in India continued their downtrend during the closing hours and ended the day in red.

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

You Can Buy Select Auto Stocks Now for Big Long-Term Returns(The 5 Minute Wrapup)

Oct 17, 2018

Irrespective of the earnings hiccups, these businesses be setting new profit records.

IPO Market Feels the Heat of the Market Crash(Sector Info)

Oct 12, 2018

The sentiments in primary market have also deteriorated amid the stock market correction. Most listed IPOs of 2018 are trading below their issue price.

Stop! Read This Before You Cancel Your SIPs(Profit Hunter)

Oct 11, 2018

Read this before you stop your SIP's in equity mutual funds.

Even If IL&FS Group Brought This Correction, this is Right Time to Buy & Sit Tight!(Chart Of The Day)

Oct 12, 2018

Even if IL&FS is the culprit, it may turn out to be a hero if you buy right and sit tight.

Why Oil Cannot Be Sold to India in Rupees(Vivek Kaul's Diary)

Oct 16, 2018

Oil is bought and sold internationally in terms of dollars. And any change to this, will be attacking the exorbitant privilege of the US dollar.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Oct 23, 2018 03:35 PM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS